Market Research Logo

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016’, provides in depth analysis on Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) targeted pipeline therapeutics.

The report provides comprehensive information on the Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B)
  • The report reviews Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) Overview
Therapeutics Development
Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Products under Development by Stage of Development
Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Products under Development by Therapy Area
Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Products under Development by Indication
Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Products under Development by Companies
Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Products under Development by Universities/Institutes
Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Companies Involved in Therapeutics Development
AbbVie Inc
Affibody AB
Anacor Pharmaceuticals, Inc.
Apexigen, Inc.
Cell Medica Limited
Handok Inc.
Immune Response BioPharma, Inc.
Novartis AG
Omnitura Therapeutics Inc.
Opsona Therapeutics Limited
Peptinov SAS
R-Pharm
Regeneron Pharmaceuticals Inc
TWi Pharmaceuticals, Inc.
Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Drug Profiles
ABT-981 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AN-4161 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APX-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
canakinumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
diacerein - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DLX-2323 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DLX-2681 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HL-2351 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IR-1000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IR-1002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IR-888 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
melittin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMN-54 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PPV-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Inhibit IL-1 Beta for Autoimmune Disorder and Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rilonacept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RPH-104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule Inflammasome Modulator Programme - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Dormant Projects
Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Discontinued Products
Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Featured News & Press Releases
Jun 27, 2016: TWi Biotechnology Announces Last Patient Enrolled in Phase 2 Study of AC-201CR for Gout Treatment
Jun 23, 2016: CHMP adopts extension to existing therapeutic indication for Canakinumab
Apr 27, 2016: Novartis receives three FDA Breakthrough Therapy Designations for Ilaris to treat rare types of Periodic Fever Syndromes
Mar 23, 2016: News Of Significant Development On The First Biotechnological Drug of Turkey from Izmir
Mar 23, 2016: Turkish signature on the biomolecules study - Hurriyet
Dec 24, 2015: TWi Biotechnology Reports Positive Interim Results from AC-201 CR Phase 2 Proof-of-Concept Study in Gout Patients
Nov 03, 2015: AbbVie to present abstract on ABT-981 at the American College of Rheumatology Annual Meeting
Oct 27, 2015: TWi Biotechnology Receives Notice of Patent Allowance in Korea for its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes
Aug 03, 2015: TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in Europe and Russia
Mar 10, 2015: TWi Biotechnology Receives Rare Disease Drug Designation for its Drug Candidate AC-203 in Taiwan
Dec 22, 2014: TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China
Dec 12, 2014: TWi Biotechnology Receives Approval of Protocol for Its Drug AC-201 Controlled-Release Tablet, Phase II Clinical Trial in Both the United States and Taiwan
Oct 21, 2014: TWi Biotechnology Receives Orphan Drug Designation for its Lead Drug Candidate AC-201 In United States
Jun 26, 2014: TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 in United States
Sep 10, 2013: TWi Biotechnology Receives Patent Allowance for Its Lead Drug Candidate AC-201 in the United States
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Number of Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Pipeline by AbbVie Inc, H2 2016
Pipeline by Affibody AB, H2 2016
Pipeline by Anacor Pharmaceuticals, Inc., H2 2016
Pipeline by Apexigen, Inc., H2 2016
Pipeline by Cell Medica Limited, H2 2016
Pipeline by Handok Inc., H2 2016
Pipeline by Immune Response BioPharma, Inc., H2 2016
Pipeline by Novartis AG, H2 2016
Pipeline by Omnitura Therapeutics Inc., H2 2016
Pipeline by Opsona Therapeutics Limited, H2 2016
Pipeline by Peptinov SAS, H2 2016
Pipeline by R-Pharm, H2 2016
Pipeline by Regeneron Pharmaceuticals Inc, H2 2016
Pipeline by TWi Pharmaceuticals, Inc., H2 2016
Dormant Projects, H2 2016
Dormant Projects (Contd..1), H2 2016
Dormant Projects (Contd..2), H2 2016
Dormant Projects (Contd..3), H2 2016
Dormant Projects (Contd..4), H2 2016
Discontinued Products, H2 2016
Discontinued Products (Contd..1), H2 2016
Discontinued Products (Contd..2), H2 2016
List of Figures
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Top 10 Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Type, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report